Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.95M | 49.32M | 73.69M | 58.56M | 31.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.95M | 49.32M | 73.69M | 58.56M | 31.11M |
| Cost of Revenue | 56.66M | 49.74M | 45.54M | 39.82M | 31.37M |
| Gross Profit | 3.29M | -417.00K | 28.15M | 18.73M | -262.00K |
| SG&A Expenses | 37.70M | 43.93M | 42.50M | 39.55M | 39.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 173.73M | 170.55M | 160.27M | 147.62M | 133.02M |
| Operating Income | -113.77M | -121.22M | -86.58M | -89.07M | -101.91M |
| Income Before Tax | -109.67M | -118.00M | -77.00M | -85.06M | -98.56M |
| Income Tax Expenses | 1.99M | -1.84M | 1.56M | -1.52M | -1.46M |
| Earnings from Continuing Operations | -111.66M | -116.16M | -78.56M | -83.54M | -97.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.66M | -116.16M | -78.56M | -83.54M | -97.10M |
| EBIT | -113.77M | -121.22M | -86.58M | -89.07M | -101.91M |
| EBITDA | -104.71M | -113.03M | -78.06M | -80.50M | -93.44M |
| EPS Basic | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 |
| Normalized Basic EPS | -0.20 | -0.23 | -0.16 | -0.18 | -0.22 |
| EPS Diluted | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 |
| Normalized Diluted EPS | -0.20 | -0.23 | -0.16 | -0.18 | -0.22 |
| Average Basic Shares Outstanding | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M |
| Average Diluted Shares Outstanding | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |